New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on February 5 and set a price target of ...
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...